Spark gene therapy for blindness could come at steep cost – BioPharma Dive
|
Spark gene therapy for blindness could come at steep cost
BioPharma Dive Early next year, Spark Therapeutics Inc.'s gene therapy Luxturna could become the first such treatment for an inherited condition to win approval in the U.S., bringing with it new hope for patients with a rare form of childhood blindness. At the same … |
